Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating... see more

Recent & Breaking News (NDAQ:BOLT)

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

GlobeNewswire January 6, 2022

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

GlobeNewswire December 16, 2021

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

GlobeNewswire December 6, 2021

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

GlobeNewswire December 2, 2021

Bolt Biotherapeutics Announces Changes to its Board of Directors

GlobeNewswire November 19, 2021

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 12, 2021

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire November 9, 2021

Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 8, 2021

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

GlobeNewswire November 3, 2021

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

GlobeNewswire October 1, 2021

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors

GlobeNewswire September 8, 2021

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire September 2, 2021

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody(TM) ISAC Programs

GlobeNewswire August 26, 2021

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire August 12, 2021

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody(TM) ISAC BDC-1001 at ASCO 2021

GlobeNewswire June 4, 2021

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

GlobeNewswire June 2, 2021

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire May 13, 2021

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody(TM) Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

GlobeNewswire April 10, 2021

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 8, 2021

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

GlobeNewswire March 31, 2021